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tion suggesting an acute coronary syndrome with impaired LV function but without coro-
nary disease. It is associated with substantial recovery of LV ejection fraction, resolution
of LV wall motion abnormalities and an excellent short-term prognosis.
1127-133 Clinical and Pathologic Characteristics of Dilated 
Cardiomyopathy in Dialysis Patients
Jiro Aoki, Yuji Ikari, Hiroyoshi Nakajima, Masaya Mori, Tokuichiro Sugimoto, Kazuhiro 
Hara, Mitsui Memorial Hospital, Tokyo, Japan
Background Some dialysis patients have impaired left ventricular (LV) function without
coronary artery disease. The pathologic changes of these patients have not been well
described. This study evaluated the clinical and pathologic characteristics of dialysis
patients with dilated cardiomyopathy (DCM). Methods We performed LV endomyocardial
biopsy on 40 dialysis patients with DCM. After LV biopsy, the patients were followed up
for mean 2.3±1.9 years. Results The pathologic characteristics were severe myocyte
hypertrophy (the mean myocyte diameter across the nucleus was 37.6±10.5 µm), myo-
cyte disarray (30%), and extensive fibrosis (the mean percent area of left ventricular
fibrosis was 22.3±18.4%). These pathologic characteristics resembled the dilated phase
of hypertophic cardiomyopathy. Their two-year survival rate was 72%. A high percent
area of LV fibrosis was the only significant predictor of cardiac death by multivariate anal-
ysis (p=0.03). The two-year event-free survival rate for cardiac death in patients with
severe fibrosis (more than 30%) was 42%, while that for patients without severe fibrosis
was 92%. Conclusion The pathologic characteristics of the heart in dialysis patients with
DCM are severe myocyte hypertrophy occasionally with disarray and a high percent area
of fibrosis. The prognosis of these patients was poor and the extent of LV fibrosis was a
strong predictor of cardiac death.
1127-134 Noninvasive Determination of Central Venous Pressure 
With a Bedside Ultrasound Device
Kelley R. Branch, Deborah H. Kwon, John M. Nicklas, University of Michigan, Ann Arbor, 
MI, University of Washington, Seattle, WA
Background: In patients with heart failure, clinical signs may not accurately reflect
hemodynamic abnormalities. To improve clinical assessment of central venous pressure
(CVP), we used a bedside ultrasound device to measure internal jugular (IJ) distention.
Methods: Forty-five subjects referred for right heart catheterization underwent cross-
sectional IJ imaging with a Site-Rite ultrasonic device (Dymax, Pittsburgh, PA). Biphasic
pulsatile distention (BiP) of an IJ, corresponding to a and v venous waves, was examined
in 36 patients. If present [(+) BiP], the maximal vertical height of the IJ fluid column was
measured from the clavicle to where the BiP disappeared while sitting upright. CVP was
measured directly by right heart catheterization and compared to the IJ ultrasound data.
Results: In patients with a measured CVP <7 mmHg, IJ BiP was not observed. In those
with a CVP >7 mmHg, BiP was present in most, but not all patients. Sensitivity for CVP
detection was 61% and specificity was 100%. The ultrasound-measured vertical IJ height
was statistically related to CVP (p = 0.006), but the correlation was poor (R2 = 0.41).
Conclusions: The absence of IJ BiP distention by cross-sectional ultrasonography while
sitting upright is a highly specific predictor of low CVP (< 7 mmHg). In patients with ele-
vated CVP, ultrasound assessment of IJ vertical distention correlates poorly with mea-
sured CVP. This demonstrates a novel, non-invasive, and readily available method for
estimation of right-sided filling pressures.
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1128-119 Coronary Flow Velocity Reserve and Asymmetric 
Dimethylarginine in Patients With Type 2 Diabetes 
Mellitus
Takayuki Kawata, Masao Daimon, Rei Hasegawa, Tomohiko Toyoda, Tai Sekine, Sachiko 
Honjyo, Kyouhei Yamamoto, Daigaku Uchida, Toshiharu Himi, Katsuya Yoshida, Issei 
Komuro, Chiba University, Chiba, Japan, Kimitsu Chuo Hospital, Chiba, Japan
Background: Endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine
(ADMA) is elevated and coronary flow velocity reserve (CFVR) is attenuated in patients
with diabetes mellitus. Although ADMA has been considered as a novel marker of athero-
sclerosis, no clinical report has yet examined the relation between ADMA and coronary
microcirculation in diabetes mellitus. We aimed to assess the relation between serum
levels of ADMA and coronary microcirculation in patients with type 2 diabetes mellitus,
using CFVR measurements with noninvasive transthoracic Doppler echocardiography
(TTDE). Methods: We studied 21 patients with type 2 diabetes mellitus (mean age
62±10 years; 12 men and 9 women, body mass index 23±4). Coronary flow velocities in
the left anterior descending artery were recorded with TTDE at rest and during hypere-
mia induced by intravenous infusion of adenosine triphosphate. CFVR was calculated as
the ratio of hyperemic to basal mean diastolic velocity. We analyzed relationship between
CFVR and venous blood samples. Results: Obtained data were as follows; CFVR
2.78±0.56, Fasting blood sugar 171±37 mg/dl, HbA1c 7.6±1.0%, Total-cholesterol
198±42 mg/dl, Triglycerides 125±78 mg/dl, HDL-cholesterol 53±15 mg/dl, and ADMA
0.5±0.08 nmol/ml. Only serum ADMA level and CFVR had significant inverse correlation
(r=-0.55, p<0.01). Moreover, multiple regression analysis showed serum ADMA level was
independently associated with CFVR (β=-0.69, p<0.01). Conclusions: This result sug-
gests that CFVR related to a serum level of ADMA. Measurement of ADMA is useful to
speculate coronary microcirculation in patients with type 2 diabetes mellitus.
1128-120 Importance of an Oral Glucose Tolerance Test in 
Identifying High Prevalence of Dysglycemia in 
Individuals at High Cardiovascular Risk
Koon K. Teo, Salim Yusuf, Barbara Ramos, Feng Zhao, Lutz Hilbrich, Craig Anderson, 
Peter Sleight, The ONTARGET/TRANSCEND Investigators, McMaster University, 
Hamilton, ON, Canada
Background Diabetes mellitus (DM) is an important cardiovascular risk factor, but
impaired glucose metabolism short of frank DM also carries excess risk. Dysglycemia
comprises (a) DM - fasting plasma glucose level =/>7 mmol/L or 2-hour glucose level
>11.1 mmol/L after a 75 gm glucose load during an oral glucose tolerance test (OGTT),
(b) impaired glucose tolerance (IGT) - fasting plasma glucose < 7 mmol/L but 2 hour glu-
cose level between 7.8 to 11.0 mmol/L during a routine OGTT, and (c) impaired fasting
glucose (IFG) - between 6.1 and 6.9 mmol/L.
Methods In this study a 2-hour 75 gm glucose load OGTT was performed, at baseline, in
consecutive patients who do not have a history of DM, enrolled into a large clinical trial.
The TRANSCEND trial includes patients, 55 years or older, at high risk for cardiovascular
events who are intolerant to ACE inhibitors, and who had been randomized to an angio-
tensin II receptor blocker, telmisartan or to placebo.
Results Of 1327 patients studied, 289 (21.8%) patients had a history of DM, an addi-
tional 121 (9.3%) patients were diagnosed to have DM during the routine baseline OGTT,
208 (15.7%) patients had IGT, 58 (4.4%) patients had IFG and 54 (4.1%) patients
refused the OGTT. Thus, at least 52.2% of the 1327 subjects have dysglycemia. History
alone identified less than half of these cases whereas a routine OGTT has been found
useful in identifying a substantial additional number of these high risk middle-aged indi-
viduals who did not know that they had abnormal glucose metabolism.
Conclusion The prevalence of dysglycemia in high-risk middle-aged individuals is higher
than generally believed and can only be identified with a routine OGTT. The identification
of dysglycemia and management of these individuals by appropriate preventive mea-
sures should contribute to a reduction of their risks.
1128-121 Manganese Superoxide Dismutase Alanine/Valine 
Polymorphism Is Associated With Coronary Artery 
Disease
Hajime Fujimoto, Nobukazu Ishizaka, Minoru Ohno, Minoru Yamakado, Ryozo Nagai, 
University of Tokyo, Tokyo, Japan, Mitsui Memorial Hospital, Tokyo, Japan
Background: Oxidative stress plays an important role in atherogenesis. Manganese
superoxide dismutase (MnSOD) is an antioxidative enzyme localized in the mitochondria.
Today, two MnSOD genotypes are known; GTT (valine) to GCT (alanine) substitution in
an amino acid codon in the signal peptide. This substitution is thought to alter the trans-
port of MnSOD into the mitochondrion, and its efficacy in fighting oxidative stress. We
investigated the association between MnSOD genotype and coronary artery disease
(CAD). Methods and Results: Blood samples were collected from 616 healthy subjects
and 442 CAD patients (those who had >75 percent diametric stenosis in their coronary
arteries) diagnosed by coronary angiography. MnSOD genotype was analyzed by fluo-
rescence-based allele-specific polymerase chain reaction and melting curve analysis
(LightCycler). The valine allele frequency was higher in the CAD patients (0.89) than in
the healthy subjects (0.84) (odds ratio=1.54, P=0.0006, Table). MnSOD polymorphism
(alanine/alanine, alanine/valine, or valine/valine) was closely related with CAD (P=0.001
by chi-square analysis, Table), but had no association with other coronary risk factors.
From multivariate logistic regression analysis, valine/valine genotype was shown to be a
coronary risk factor independent of other risk factors (odds ratio=1.76, P=0.003). Conclu-
sion: Valine allele is closely related to the susceptibility of CAD. The valine/valine geno-
type of MnSOD is a genetic risk factor for CAD.
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val/val, % (n) 69.8 (430) 79.8 (353) 0. 001
(chi-square 
analysis)
ala/val, % (n) 28.3 (174) 18.6 (82)
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val (ala / val)
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